Zonisamide is a sulfonamide antiepileptic drug that is a 1,2 benzisoxazole derivative and is the first compound from this group of chemicals to be used as an antiepileptic drug. It is chemically unrelated to other antiepileptic medications. First used in Japan in 1972 to treat psychiatric disorders, it has been in use there to treat epilepsy since at least 1990.
It was FDA approved in the United States in 2000 for use as adjunctive therapy for treatment of partial seizures in adults.
It is not FDA approved in the United States for use in children, but clinical studies have shown efficacy and benefits.
Small clinical studies have indicated that zonisamide is effective for other types of epilepsy and epilepsy syndromes like infantile spasms, progressive myoclonus epilepsy, Lennox- Gastaut syndrome, simple partial seizures, complex partial seizures, and myoclonic seizures.
Only a few clinical trials have evaluated the use of zonisamide as monotherapy for the treatment of epilepsy. A systematic review of zonisamide therapy alone for partial seizures in children concluded there was insufficient evidence to support zonisamide monotherapy. It may be effective as a single agent for epilepsy. However, larger double-blind clinical trials are needed before zonisamide monotherapy can be recommended.
There have been clinical trials for zonisamide use and benefits in patients with mania and acute psychotic conditions.
It also has shown efficacy in patients with neuropathic pain.
Some studies report improvement in Parkinson disease symptoms when added to their other medications.
Studies suggest zonisamide may be as effective as propranolol in patients with head tremor or essential tremors.
Zonisamide acts through blockade of voltage-dependent sodium and T-type calcium channels. It possibly also inhibits glutamate release. It is a weak inhibitor of carbonic anhydrase, although this action is not responsible for its antiepileptic activity. 
Zonisamide is rapidly absorbed and evenly distributed following oral administration. Maximum concentration is achieved within 2 to 5 hours. Food delays the time to maximum concentration but not bioavailability. If taken with food, it may take up to 4 to 6 hours to reach peak plasma levels. Bioavailability is high, but because of lack of availability of parenteral product, absolute bioavailability in humans is unknown. It is metabolized mainly by cytochrome P450 3A4. Intestinal 3A4 may account for decreased bioavailability of oral preparation.
Distribution and protein binding
Zonisamide has a dose-dependent decrease in volume of distribution. It has saturable binding to erythrocytes, especially to intracellular carbonic anhydrase. It binds to red blood cells (RBC) and is found in higher concentrations in RBCs than in plasma. Whole blood zonisamide concentration is non-linear as the dosage increases; however, plasma zonisamide concentration is linear with increased doses. Around 40% of zonisamide is bound to plasma proteins, especially albumin.
Metabolism and clearance
Following oral administration, the half-life of zonisamide is estimated at 50 to 69 hours for plasma and 105 hours for RBCs. It takes up to 14 days to reach steady-state levels after taking a stable dose of zonisamide. Less than 30% of it is eliminated unchanged in urine. Most of the drug undergoes extensive hepatic metabolism. The major metabolite of Zonisamide is 2-sulfamoylacetylphenol (SMAP), formed by liver microsomal enzymes primarily through cytochrome P450 3A4. It is metabolized to a lesser extent by CYP 2C19 and CYP 3A5. Metabolites are pharmacologically inactive and are excreted primarily by kidneys.
Recommended initial dose of zonisamide is 100 to 200 mg daily for adults and 2 to 4 mg/kg/day for children. Once or twice daily dosing is used. The dose should be increased at two-week intervals to achieve a target maintenance dose of 300 to 400 mg daily in adults and 4 to 8 mg/kg in children. Doses up to 600 mg/day have been used in adults, but studies have indicated more adverse effects and no greater efficacy for doses more than 400 mg/day. The recommended doses are associated with a steady state plasma concentration of 10 to 38 mcg/mL. It is recommended to maintain zonisamide concentrations less than 30 to 40 mcg/mL.
It is available as tablets and capsules for oral use. Parenteral formulation of zonisamide is not available for use.
Caution should be used in patients with hepatic and renal impairment; slower titration and frequent monitoring are advised. It should not be used in patients with renal impairment with glomerular filtration rate less than 50 mL/min.
Dizziness, somnolence, anorexia, ataxia, fatigue, abnormal thinking, and confusion are common side effects of zonisamide use.
Zonisamide can cause mild to moderate weight loss. Obese patients or those who experienced weight gain associated with the use of other antiepileptic drugs may benefit from the addition of zonisamide to their regimen.
Renal calculi are more common in individuals who have been taking zonisamide for at least six months, have a family history of nephrolithiasis, or are also taking other antiepileptic drugs. Zonisamide is not contraindicated in patients with a history of kidney stones, but care should be taken in patients on zonisamide and they should maintain adequate hydration to maintain good urine flow.
Allergic reactions are rare but have been reported. A rash is the predominant allergic-type reaction reported. Zonisamide is chemically related to sulfonamide drugs; caution should be taken when using zonisamide in patients with prior allergic reaction to sulfa agents.
Mild, relative neutropenia has been observed in some individuals.
Oligohidrosis can occur, causing decreased sweating and hyperthermia. This has been reported more in children. Children on zonisamide should not be exposed to extreme heat for prolonged periods.
Zonisamide can produce metabolic acidosis as it has carbonic anhydrase inhibitor activity. Serum bicarbonate should be checked before starting treatment and regularly thereafter, especially in individuals with impaired pulmonary or renal function.
Zonisamide may alter cognition and behavior in some individuals. The true incidence of these adverse effects is unknown. Most of the reports of cognitive or behavioral problems have been in patients taking multiple antiepileptic drugs.
Limited data are available on the teratogenic effects of zonisamide. Reports conclude that zonisamide is associated with no greater risk of teratogenicity than other antiepileptic drugs.
Zonisamide is contraindicated in patients with hypersensitivity or severe allergic reaction to zonisamide or sulfonamides.
Serum bicarbonate, BUN/creatinine, and CBC should be checked before initiating Zonisamide treatment and periodically thereafter. Signs and symptoms of depression and behavior change should be monitored closely in patients taking zonisamide. Monitoring of serum levels is recommended for all patients to ensure appropriate dosing. Serum levels may not correlate with the dose because it has concentration-dependent erythrocyte binding. Patient response usually correlates well with serum level.
Limited data are available on zonisamide overdose, and there are no cases reported thus far for monotoxicity with zonisamide. When acute or chronic zonisamide toxicity is suspected, immediate medical attention should be sought, and poison control should be contacted. Plasma concentration of zonisamide should be measured. Patients should be monitored closely and symptomatically treated. Overdose symptoms may include nausea, vomiting, somnolence, central nervous system depression, metabolic acidosis, and polyuria.
While zonisamide treatment is usually initiated by the neurologist, patient follow up is usually by the primary care provider and nurse practitioner. Patients being treated with zonisamide need monitoring of their renal function and CBC at regular intervals. Further, signs and symptoms of depression and behavior change should be monitored closely. Monitoring of serum levels of the drug is recommended for all patients to ensure appropriate dosing. Serum levels may not correlate with the dose because it has concentration-dependent erythrocyte binding. Patient response usually correlates well with serum level. Patient compliance with the medication should be reinforced at every visit nurse and pharmacist.
|||Sano H,Nambu A, The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. Neurochemistry international. 2019 Jan 11; [PubMed PMID: 30639196]|
|||Ueno SI,Saiki S,Fujimaki M,Takeshige-Amano H,Hatano T,Oyama G,Ishikawa KI,Yamaguchi A,Nojiri S,Akamatsu W,Hattori N, Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells. 2018 Dec 29; [PubMed PMID: 30597973]|
|||Galgani A,Palleria C,Iannone LF,De Sarro G,Giorgi FS,Maschio M,Russo E, Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. Frontiers in neurology. 2018; [PubMed PMID: 30581412]|
|||Hara N,Nezu T,Kobatake K,Morino H,Kawakami H,Maruyama H, Treatment of intractable resting tremor of spinocerebellar ataxia 42 with zonisamide. Journal of the neurological sciences. 2019 Jan 15; [PubMed PMID: 30448718]|
|||Brigo F,Lattanzi S,Igwe SC,Behzadifar M,Bragazzi NL, Zonisamide add-on therapy for focal epilepsy. The Cochrane database of systematic reviews. 2018 Oct 18; [PubMed PMID: 30335200]|
|||Park KM,Lee BI,Shin KJ,Ha SY,Park J,Kim SE,Kim SE, Efficacy, tolerability, and blood concentration of zonisamide in daily clinical practice. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2018 Nov 13; [PubMed PMID: 30446366]|
|||Verrotti A,Striano P,Iapadre G,Zagaroli L,Bonanni P,Coppola G,Elia M,Mecarelli O,Franzoni E,Liso P,Vigevano F,Curatolo P, The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure. 2018 Dec; [PubMed PMID: 30391662]|
|||Kanner AM,Ashman E,Gloss D,Harden C,Bourgeois B,Bautista JF,Abou-Khalil B,Burakgazi-Dalkilic E,Park EL,Stern J,Hirtz D,Nespeca M,Gidal B,Faught E,French J, Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy currents. 2018 Jul-Aug; [PubMed PMID: 30254527]|